At a glance
ClinicalIndex Comparison RecordN/ACompleted· 54 enrolled
Drug / intervention
Albuterol eMDPI DScombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of ProAir Digihaler in Chronic Obstructive Pulmonary Disease (COPD) - Characterization of Inhalation Metrics From a Cohort of Patient At-risk for Acute Exacerbation of COPD (AECOPD) in an Outpatient Setting
In Brief
A clinical study evaluating Albuterol eMDPI DS for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 54 participants across 2 sites.
Detailed Summary
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics \[peak inspiratory flow (PIF), inhalation volume, number of inhalation events\] amongst COPD patients in the ambulatory setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Timeline
N/ACompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedFeb 15, 2022
Enrollment StartMar 1, 2022
Primary CompletionFeb 13, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.4 years ago
Interventions
Albuterol eMDPI DScombination
Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices: Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)